TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Genfit SA ( (GNFT) ) just unveiled an update.
On November 10, 2025, GENFIT announced a research collaboration with EVerZom to advance exosome-based regenerative technology for treating Acute-On-Chronic Liver Failure (ACLF). This partnership will explore the efficacy of EVerZom’s investigational drug candidate, EViv, with GENFIT having an exclusive option to license the drug for clinical development pending successful proof-of-concept results. This collaboration combines EVerZom’s expertise in exosome technology with GENFIT’s leadership in ACLF, potentially accelerating therapeutic progress and enhancing GENFIT’s position in the regenerative medicine field.
The most recent analyst rating on (GNFT) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Genfit SA stock, see the GNFT Stock Forecast page.
Spark’s Take on GNFT Stock
According to Spark, TipRanks’ AI Analyst, GNFT is a Neutral.
Genfit SA’s overall stock score is primarily influenced by its financial performance, which shows a positive recovery trajectory. However, technical indicators suggest bearish momentum, and the valuation is weak due to the negative P/E ratio and lack of dividend yield. These factors collectively result in a moderate overall score.
To see Spark’s full report on GNFT stock, click here.
More about Genfit SA
GENFIT is a biopharmaceutical company focused on developing therapies for rare and life-threatening liver diseases, including Acute on-chronic Liver Failure (ACLF), acute decompensation, and hepatic encephalopathy. The company has a strong history in liver disease research and development, with a portfolio that spans various stages of development. GENFIT is headquartered in Lille, France, and is listed on both the Nasdaq and Euronext markets.
Average Trading Volume: 6,463
Technical Sentiment Signal: Strong Sell
Current Market Cap: $197.5M
Find detailed analytics on GNFT stock on TipRanks’ Stock Analysis page.